| Literature DB >> 35421271 |
Honghai Fu1, Dianguo Zhao2, Legang Sun1, Yumei Huang3, Xiangrui Ma1.
Abstract
BACKGROUND: Autophagy plays a vital role in the progression of the tumor. We aimed to investigate the expression, prognostic value, and immune infiltration of autophagy-related genes in oral carcinoma via bioinformatics analysis.Entities:
Keywords: FADD; autophagy; bioinformatics; immune infiltrates; oral cancer
Mesh:
Substances:
Year: 2022 PMID: 35421271 PMCID: PMC9102594 DOI: 10.1002/jcla.24417
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 3.124
FIGURE 1Volcano plot distribution of gene expression data between normal and OSC samples. (A) Volcano plot of GSE146483 database. (B) Volcano plot of GSE23558 database. DEGs were screened based on |log2FC| >1 and p < 0.05
FIGURE 2Identifying the autophagy‐related DEGs among GSE146483 and GSE23558. (A) Venn diagram of the upregulated DEGs. (B) Venn diagram of the downregulated DEGs
Communal differentially expressed genes (DEGs) between GSE146483 and GSE23558 microarray data
| Category | DEGs |
|---|---|
| Upregulated | EPHB2, E2F1, EIF2AK1, CHEK1, AURKA, BID, BIRC5, CSF2, TNF, ACP2, BRCA1, PTPN2, APOL6, SERPINH1, FADD, EGFR, KRT18, EIF2AK2 |
| Downregulated | SVIP, NOS1, NUPR1, CAPNS2, CFLAR, MAP1LC3A, GAB1, TP53INP1, SESN1, ATG9B, RRAGD, DEPTOR, GJA4, LRRK2, RAB5A, TMEM74, ULK2, TBC1D9, IGF1, DCN, HTR2B, TLR7, AGT, NFE2L2, PRKAA2, GRID1, IKBKB, SYNPO2, CXCL12, PARK2, CAPN14 |
FIGURE 3Functional enrichment analyses of upregulated DEGs. (A) The top 10 enriched GO‐BP terms for upregulated DEGs. (B) The top 10 enriched KEGG pathways for upregulated DEGs
Enrichment analyses of upregulated DEGs
| Category | Description |
| Count | Genes |
|---|---|---|---|---|
| GO‐BP | Apoptotic signaling pathway | 1.16E−09 | 17 | BID, BRCA1, CSF2, E2F1, KRT18, PTPN2, TNF, FADD, EIF2AK1, BIRC5, CHEK1, EGFR, AURKA, EIF2AK2, EPHB2, ACP2, APOL6 |
| Regulation of cellular response to stress | 3.22E−09 | 12 | BID, BRCA1, CHEK1, EGFR, EIF2AK2, PTPN2, TNF, EIF2AK1, FADD, AURKA, E2F1, KRT18 | |
| Extrinsic apoptotic signaling pathway | 3.55E−09 | 6 | BID, BRCA1, CSF2, KRT18, TNF, FADD | |
| Regulation of mitotic cell cycle | 7.96E−09 | 7 | BID, BRCA1, CHEK1, E2F1, EGFR, AURKA, TNF | |
| Regulation of mitotic cell cycle phase transition | 2.27E−08 | 6 | BID, BRCA1, CHEK1, E2F1, EGFR, AURKA | |
| Macrophage differentiation | 2.43E−08 | 4 | CSF2, PTPN2, FADD, EIF2AK1 | |
| Regulation of extrinsic apoptotic signaling pathway | 3.36E−08 | 5 | BID, BRCA1, CSF2, TNF, FADD | |
| Regulation of apoptotic signaling pathway | 6.39E−08 | 6 | BID, BRCA1, CSF2, PTPN2, TNF, FADD | |
| Peptidyl‐tyrosine phosphorylation | 8.83E−08 | 12 | CSF2, EGFR, EPHB2, EIF2AK2, PTPN2, TNF, E2F1, AURKA, KRT18, FADD, BID, BRCA1 | |
| Peptidyl‐tyrosine modification | 9.25E−08 | 6 | CSF2, EGFR, EPHB2, EIF2AK2, PTPN2, TNF | |
| KEGG | Hepatitis C | 7.45E−12 | 11 | BID, E2F1, EGFR, EIF2AK2, TNF, FADD, EIF2AK1, BIRC5, BRCA1, SERPINH1, AURKA |
| Epstein–Barr virus infection | 2.27E−08 | 6 | BID, E2F1, EIF2AK2, TNF, FADD, EIF2AK1 | |
| Hepatitis B | 7.43E−08 | 5 | BIRC5, BID, E2F1, TNF, FADD | |
| Platinum drug resistance | 1.24E−07 | 4 | BIRC5, BID, BRCA1, FADD | |
| Apoptosis‐multiple species | 1.18E−06 | 3 | BIRC5, BID, FADD | |
| Apoptosis | 1.6E−06 | 4 | BIRC5, BID, TNF, FADD | |
| Measles | 2.75E−06 | 4 | BID, EIF2AK2, FADD, EIF2AK1 | |
| Pathways in cancer | 3.9E−06 | 5 | BIRC5, BID, E2F1, EGFR, FADD | |
| Herpes simplex infection | 5.13E−06 | 4 | EIF2AK2, TNF, FADD, EIF2AK1 | |
| HTLV‐I infection | 1.85E−05 | 4 | CHEK1, CSF2, E2F1, TNF |
FIGURE 4Functional enrichment analyses of downregulated DEGs. (A) The top 10 enriched GO‐BP terms for downregulated DEGs. (B) The top 10 enriched KEGG pathways for downregulated DEGs
Enrichment analyses of downregulated DEGs
| Category | Description |
| Count | Genes |
|---|---|---|---|---|
| GO‐BP | Autophagy | 4.32E−20 | 16 | DCN, HTR2B, PRKN, PRKAA2, RAB5A, ULK2, NUPR1, SESN1, RRAGD, AP1LC3A, TP53INP1, LRRK2, TMEM74, SYNPO2, SVIP, ATG9B |
| Process utilizing autophagic mechanism | 4.32E−20 | 16 | DCN, HTR2B, PRKN, PRKAA2, RAB5A, ULK2, NUPR1, SESN1, RRAGD, MAP1LC3A, TP53INP1, LRRK2, TMEM74, SYNPO2, SVIP, ATG9B | |
| Macroautophagy | 2.45E−18 | 13 | DCN, PRKN, PRKAA2, RAB5A, ULK2, NUPR1, SESN1, MAP1LC3A, TP53INP1, LRRK2, TMEM74, SYNPO2, ATG9B | |
| Autophagosome assembly | 1.29E−13 | 8 | RAB5A, ULK2, NUPR1, MAP1LC3A, TP53INP1, LRRK2, SYNPO2, ATG9B | |
| Autophagosome organization | 1.79E−13 | 8 | RAB5A, ULK2, NUPR1, MAP1LC3A, TP53INP1, LRRK2, SYNPO2, ATG9B | |
| Regulation of autophagy | 1.12E−12 | 10 | DCN, HTR2B, PRKN, PRKAA2, NUPR1, SESN1, RRAGD, TP53INP1, LRRK2, SVIP, IGF1, NFE2L2 | |
| Positive regulation of cellular catabolic process | 1.98E−11 | 10 | DCN, IGF1, NFE2L2, PRKN, PRKAA2, NUPR1, SESN1, TP53INP1, LRRK2, SVIP | |
| Vacuole organization | 1.98E−11 | 8 | RAB5A, ULK2, NUPR1, MAP1LC3A, TP53INP1, LRRK2, SYNPO2, ATG9B | |
| positive regulation of autophagy | 6.51E−11 | 7 | DCN, PRKN, PRKAA2, SESN1, TP53INP1, LRRK2, SVIP | |
| Positive regulation of catabolic process | 7.88E−11 | 10 | DCN, IGF1, NFE2L2, PRKN, PRKAA2, NUPR1, SESN1, TP53INP1, LRRK2, SVIP | |
| KEGG | Autophagy‐animal | 5.26E−09 | 6 | PRKAA2, CFLAR, ULK2, RRAGD, DEPTOR, ATG9B, IGF1, IKBKB, SESN1, MAP1LC3A, TP53INP1 |
| Regulation of autophagy | 6.33E−09 | 6 | PRKAA2, CFLAR, ULK2, RRAGD, DEPTOR, ATG9B | |
| mTOR signaling pathway | 1.42E−08 | 6 | IGF1, IKBKB, PRKAA2, ULK2, RRAGD, DEPTOR | |
| NF‐kappa B signaling pathway | 0.000156 | 3 | IKBKB, CXCL12, CFLAR | |
| Ras signaling pathway | 0.000181 | 4 | GAB1, IGF1, IKBKB, RAB5A | |
| Longevity regulating pathway | 0.000234 | 3 | IGF1, PRKAA2, SESN1 | |
| foxo signaling pathway | 0.000458 | 3 | IGF1, IKBKB, PRKAA2 | |
| Protein processing in endoplasmic reticulum | 0.000801 | 3 | NFE2L2, PRKN, SVIP | |
| Proteoglycans in cancer | 0.00143 | 3 | DCN, GAB1, IGF1 | |
| PI3K‐Akt signaling pathway | 0.006205 | 3 | IGF1, IKBKB, PRKAA2 |
FIGURE 5Identification of hub genes. (A) PPI network of the overlapping DEGs. (B) The top 5 hub genes were identified based on the degree of nodes
FIGURE 6Expression level of FADD in oral cancer. (A) The mRNA expression level of Fais DD based on TCGA the database. (B) The mRNA expression level of FADD is based on the GSE78060 dataset. (C) Protein levels of FADD in normal oral tissue (staining: not detected; intensity: negative; and quantity: none). (D) Protein levels of FADD in tumor tissue (staining: medium; intensity: moderate; and quantity: >75%)
FIGURE 7ROC curve and overall survival curve for FADD in oral cancer. (A) ROC curve revealed that FADD exhibited an AUC value of 0.939 to distinguish between normal samples and oral cancer samples. (B) Higher FADD expression resulted in shorter overall survival
FIGURE 8Enrichment plots of GSEA. The findings revealed that the positive regulation of immune response (A), lymphocyte activation (B), leukocyte‐mediated immunity (C), innate immune response (D), endocytosis (E), and adaptive immune response (F) were significantly enriched in oral cancer samples with high FADD expression
FIGURE 9FADD expression is related to immune cell infiltrations in oral cancer. (A) Correlation analysis between FADD expression and immune cells. (B) The copy number variations of FADD affect the infiltrating levels of dendritic cells, neutrophil, macrophages, CD4 + T cells, CD8 + T cells, and B cells. (C) The differential expression of tumor‐infiltrating immune cells in high and low FADD expression groups (ns: no significance, *p < 0.05, **p < 0.01, and ***p < 0.001)